Molbio Diagnostics Limited Share Price & Analysis
₹1160.50+2.23%Updated 4 Sept 2026, 03:30 pm IST
LTP
₹1160.50+2.23%Open
₹1139.90High
₹1177.00Low
₹1117.20Close
₹1160.5052W High
₹1265.0052W Low
₹926.00Volume
594KLot Size
1Sector
HealthcareMarket Cap
₹13K CrFace Value
₹1Mid Cap
Price Chart
Candle
Range
Fundamentals
P/E
53.60Sector P/E
54.70P/B
—EPS
₹14.77ROE
15.60%ROCE
18.50%D/E Ratio
0.38Div Yield
0.00%Book Value
—Strengths
- Strong return on equity (ROE 15.6%)
- Efficient capital deployment (ROCE 18.5%)
- Low debt relative to equity (D/E 0.4x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Corporate Events
To consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026.
Results4 Sept 2026
Financials
Quarterly Results
| Metric | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | ₹408 Cr 27.3% | ₹561 Cr 461.0% | ₹100 Cr |
| Op. Profit | ₹101 Cr 36.5% | ₹159 Cr 1093.8% | ₹-16 Cr |
| OPM | 25.0% 10.7% | 28.0% 275.0% | -16.0% |
| Net Profit | ₹53 Cr 44.8% | ₹96 Cr 500.0% | ₹-24 Cr |
| EPS (₹) | 5.21 35.4% | 8.06 176.7% | -10.51 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| Revenue | ₹1.4K Cr 41.8% | ₹1.0K Cr 21.9% | ₹837 Cr |
| Expenses | ₹1.1K Cr 48.2% | ₹760 Cr 26.2% | ₹602 Cr |
| Op. Profit | ₹320 Cr 23.1% | ₹260 Cr 11.1% | ₹234 Cr |
| OPM | 22.0% 15.4% | 26.0% 7.1% | 28.0% |
| Other Income | ₹9 Cr 325.0% | ₹-4 Cr 91.8% | ₹-49 Cr |
| Interest | ₹33 Cr 83.3% | ₹18 Cr 28.6% | ₹14 Cr |
| Depreciation | ₹64 Cr 42.2% | ₹45 Cr 9.8% | ₹41 Cr |
| PBT | ₹231 Cr 19.1% | ₹194 Cr 49.2% | ₹130 Cr |
| Tax % | 29.0% 0.0% | 29.0% 19.4% | 36.0% |
| Net Profit | ₹164 Cr 18.0% | ₹139 Cr 65.5% | ₹84 Cr |
| EPS (₹) | 14.77 77.0% | 64.34 85.8% | 452.37 |
| Div Payout | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
Liabilities | |||
| Equity Capital | ₹11 Cr 450.0% | ₹2 Cr 0.0% | ₹2 Cr |
| Reserves | ₹1.2K Cr 19.9% | ₹966 Cr 17.7% | ₹821 Cr |
| Borrowings | ₹450 Cr 206.1% | ₹147 Cr 20.1% | ₹184 Cr |
| Other Liabilities | ₹496 Cr 43.4% | ₹346 Cr 64.0% | ₹211 Cr |
| Total Liabilities | ₹2.1K Cr 44.8% | ₹1.5K Cr 20.0% | ₹1.2K Cr |
Assets | |||
| Fixed Assets | ₹536 Cr 84.8% | ₹290 Cr 0.3% | ₹289 Cr |
| CWIP | ₹11 Cr 59.3% | ₹27 Cr 1250.0% | ₹2 Cr |
| Investments | ₹6 Cr 87.0% | ₹46 Cr 666.7% | ₹6 Cr |
| Other Assets | ₹1.6K Cr 42.1% | ₹1.1K Cr 19.3% | ₹921 Cr |
| Total Assets | ₹2.1K Cr 44.8% | ₹1.5K Cr 20.0% | ₹1.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| Operating CF | ₹50 Cr 82.6% | ₹287 Cr 2770.0% | ₹10 Cr |
| Investing CF | ₹-54 Cr 56.1% | ₹-123 Cr 173.3% | ₹-45 Cr |
| Financing CF | ₹276 Cr 1161.5% | ₹-26 Cr 18.8% | ₹-32 Cr |
| Net Cash Flow | ₹273 Cr 97.8% | ₹138 Cr 306.0% | ₹-67 Cr |
| Free Cash Flow | ₹1 Cr 99.6% | ₹232 Cr 3414.3% | ₹-7 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| Debtor Days | 103d 6.2% | 97d 47.8% | 186d |
| Inventory Days | 285d 25.8% | 384d 13.6% | 338d |
| Days Payable | 126d 37.9% | 203d 101.0% | 101d |
| Cash Conv. Cycle | 261d 6.1% | 278d 34.3% | 423d |
| Working Capital Days | 116d 9.4% | 128d 36.0% | 200d |
| ROCE | 18.0% 14.3% | 21.0% | — |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Molbio Diagnostics Limited share price today?
Molbio Diagnostics Limited (MOLBIO) is currently trading at ₹1,160.5 on NSE, up 2.23% as of the last market session. Prices update daily after market close on MarketNetra.
Is Molbio Diagnostics Limited available in F&O (Futures & Options)?
Yes, Molbio Diagnostics Limited (MOLBIO) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Molbio Diagnostics Limited 52-week high and low?
Molbio Diagnostics Limited's 52-week high is ₹1,265 and the 52-week low is ₹926. The current price of ₹1,160.5 is 8.3% below the 52W high.
What is Molbio Diagnostics Limited P/E ratio?
Molbio Diagnostics Limited's current P/E ratio is 53.6. This indicates the market is paying ₹53.6 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Molbio Diagnostics Limited options?
Molbio Diagnostics Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade MOLBIO options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.